Evidence map›Paper›PMID 36092352›Full record

ArticleJournal of gastrointestinal oncology2022

Low CPEB1 levels may predict the benefit of 5-fluorouracil treatment in patients with colon or stomach adenocarcinoma.

Jing-Zhu Cao, Dan-Dan Niu, Zhi-Ping Huang, Yong-Gang Hong, Zhen-Guang Wang, Le Yang, Bo-Lun Zhao, Guang-Lei Qiao, Liu Ouyang

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of gastrointestinal oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 1 country.

Jing-Zhu Cao *Department of Endocrinology and Metabolism, Changhai Hospital, Naval Medical University, Shanghai, China.
Dan-Dan Niu *Department of Anesthesiology, Huashan Hospital, Fudan University, Shanghai, China.
Zhi-Ping Huang *Department of Hepatobiliary Surgery, General Hospital of Southern Theatre Command, Guangzhou, China.
Yong-Gang Hong *Department of Colorectal Surgery, Changhai Hospital, Naval Medical University, Shanghai, China.
Zhen-Guang WangThe Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.
Le YangThe Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.
Bo-Lun ZhaoSchool of Nursing, Dalian University, Dalian, China.
Guang-Lei QiaoDepartment of Oncology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Liu OuyangDepartment of the HBP Surgery, Changhai Hospital, Naval Medical University, Shanghai, China.
Second Military Medical University · CNChanghai Hospital · CNDalian University · CNEastern Hepatobiliary Surgery Hospital · CNFudan University · CNThird Affiliated Hospital of Southern Medical University · CNTongren Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: For patients with colon or stomach adenocarcinoma, 5-fluorouracil (5-FU) is an essential component of systemic chemotherapy in the palliative and adjuvant settings. The post-transcriptional regulatory factor cytoplasmic polyadenylation element-binding protein 1 (CPEB1) has been reported to be linked to tumor metastasis. This study aimed to investigate the relationship between CPEB1 expression and 5-FU treatment response in patients with colon and stomach adenocarcinomas. Methods: The expression of Results: The expression levels of Conclusions: Our results indicate that the level of CPEB1 expression may be valuable for predicting the benefit of 5-FU treatment for patients with colon and stomach adenocarcinomas. We therefore propose that low CPEB1 expression may represent a novel biomarker for personalized 5-FU therapy.

Indexed as

5-fluorouracil treatment (5-FU treatment)biomarkercolon adenocarcinomaCytoplasmic polyadenylation element-binding protein 1 (CPEB1)stomach adenocarcinoma

Identifiers

PMID36092352
PMCPMC9459193
OpenAlexW4285164051

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.